Abstract
Zusammenfassung.Zielsetzung: Die Pathogenese der Komorbidität der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) und Substanzabhängigkeit hat große klinische Relevanz, da nach klinisch-epidemiologischer Erfahrung bei ADHS-Patienten einerseits häufig eine komorbide Substanzabhängigkeit vorliegt, andererseits sich daraus erhebliche Konsequenzen für das therapeutische und diagnostische Procedere ergeben. Zusammenhänge von ADHS und Substanzstörungen: Neben der „Dopaminmangelhypothese“ bei ADHS sind unter anderem das Konzept des „Sensation-Seekings“ (Zuckerman, 1979) und die „Selbstmedikations-Hypothese“ (Khantzian, 1985) auch im Zusammenhang mit anderen komorbiden Störungen von Belang. Schlussfolgerungen für die Praxis: Die Diagnostik von ADHS-Patienten sollte Substanzstörungen und andere psychische Komorbiditäten berücksichtigen. Klinische Implikationen für die Pharmakotherapie lassen sich insbesondere aus der „Dopaminmangelhypothese“ und den beobachteten depressiven Symptomen bei ADHS-Patienten ableiten: neben der möglichen Behandlung mit Methylphenidat wird daher vorgeschlagen, den therapeutischen Wert von selektiven Dopamin- oder Noradrenalin-Wiederaufnahme-Hemmern und darüber hinaus insbesondere auch psychotherapeutische Behandlungsverfahren zu nutzen.
Abstract.Aim: An understanding of the pathogenesis of the comorbidity of attention deficit/hyperactivity disorder (ADHD) and substance use disorders is clinically relevant. According to clinical-epidemiological expertise, ADHD patients often show a comorbid substance dependence, resulting in significant consequences for therapeutic and diagnostic procedures. Relationship of ADHD and substance use disorders: In addition to the “dopamine-deficiency hypothesis” for ADHD, the concept of “sensation-seeking” (Zuckerman, 1979) and the “self-medication hypothesis” (Khantzian, 1985) are relevant for understanding the comorbidity of ADHD and substance use disorders. Clinical implications: Diagnostic routines of ADHD patients should consider substance use disorders and other psychiatric comorbidities. The “dopamine-deficiency hypothesis” and the observed depressive symptoms in ADHD patients support clinical pharmacological implications: Besides the possible treatment with methylphenidate the therapeutic value of substances such as SSRI and SNRI should be considered – as well as a psychotherapy.
Literatur
2007). Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined–type ADHD. American Journal of Psychiatry, 164, 674 – 677.
(1995). Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. American Journal of Psychiatry, 152, 1652 – 1658.
(1998). Does attention-deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biological Psychiatry, 44, 269 – 273.
(1993). History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. Comprehensive Psychiatry, 34, 75 – 82.
(1986). A unified biosocial theory of personality and its role in the development of anxiety states. Psychiatric Developments, 4, 167 – 226.
(1996). Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD). Psychopharmacological Bulletin, 32, 67 – 73.
(2015). Might the temperament be a bias in clinical study on attention-deficit hyperactivity disorder (ADHD)? Novelty Seeking dimension as a core feature of ADHD. Psychiatry Research, 227, 333 – 338.
(1999). Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet, 354, 2132 – 2133.
(2000). Attention deficit hyperactivity disorder: binding of [99mTc]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment. European Journal of Nuclear Medicine, 27, 1518 – 1524.
(1998). DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18] fluorodopa positron emission tomographic study. The Journal of Neuroscience, 18, 5901 – 5907.
(2002). Temporal association between childhood psychopathology and substance use disorders: findings from a sample of adults with opioid or alcohol dependency. Psychiatry Research, 109, 245 – 253.
(2006). The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. American Journal of Psychiatry, 163, 716 – 723.
(1983). An extreme case of cocaine dependence and marked improvement with methylphenidate treatment. American Journal of Psychiatry, 140, 784 – 785.
(1985). The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry, 142, 1259 – 1264.
(2010). European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry, 10, 67.
(2002). Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Alkoholikern. Nervenheilkunde, 21, 156 – 159.
(2002). Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. International Journal of Neuropsychopharmacology, 5, 111 – 113.
(1996). Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology (Berlin), 123, 55 – 63.
(1995). Attention-deficit hyperactivity disorder and substance abuse: relationships and implications for treatment. Harvard Review of Psychiatry, 2, 246 – 258.
(1993). Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Archives of General Psychiatry, 50, 565 – 576.
(2008). Lifetime criminality among boys with attention deficit hyperactivity disorder: a prospective follow-up study into adulthood using official arrest records. Psychiatry Research, 160, 237 – 246.
(2001). Antecedents of opioid dependence and personality disorder: Attention-deficit/hyperactivity disorder and conduct disorder. European Archives of Psychiatry and Clinical Neuroscience, 251, 42 – 47.
(2007). Nicotine and alcohol dependence in patients with comorbid attention-deficit/hyperactivity disorder (ADHD). Alcohol and Alcoholism, 42, 539 – 543.
(2008). Comorbidity of alcohol and substance dependence with attention-deficit/hyperactivity disorder (ADHD). Alcohol and Alcoholism, 43, 300 – 304.
(2010). ADHS und Abhängigkeitserkrankungen. Persönlichkeitsstörungen, 14, 48 – 60.
(1996). Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature, 382, 255 – 257.
(2000). Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. Journal of the American Academy of Child & Adolescent Psychiatry, 39, 1424 – 1431.
(2004). Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. European Archives of Psychiatry and Clinical Neuroscience, 254, 365 – 371.
(2009). Inattention and hyperactivity dimensions of ADHD are associated with different personality profiles. Psychopathology, 42, 108 – 112.
(2006). Komorbidität der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung im Erwachsenenalter: Perspektiven für die Diagnostik mit dem BAS-E. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 54, 123 – 132.
(2000). Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. Journal of Clinical Psychiatry, 61, 244 – 251.
(2009). Personality characteristics of adults with autism spectrum disorders or attention deficit hyperactivity disorder with and without substance use disorders. The Journal of Nervous and Mental Disease, 197, 450 – 454.
(1998). Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. American Journal of Psychiatry, 155, 693 – 695.
(2001). Attention deficit/hyperactivity disorder and substance abuse. Diagnostic and therapeutic considerations. Annals of the New York Academy of Sciences, 931, 251 – 270.
(2009): Psychopharmacology: concepts and opinions about the use of stimulant medications. Journal of Child Psychology and Psychiatry, 50, 180 – 93.
(2007). Modeling the pathways linking childhood hyperactivity and substance use disorder in young adulthood. Psychology of Addictive Behaviors, 21, 266 – 271.
(2007). Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder. Journal of Clinical Psychiatry, 68 Suppl 11, 23 – 30.
(2004). Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study. Journal of the American Academy of Child & Adolescent Psychiatry, 43, 199 – 205.
(2001). Venlafaxine Treatment of Patients With Comorbid Alcohol/Cocaine Abuse and Attention-Deficit/Hyperactivity Disorder: A Pilot Study. Journal of Clinical Psychopharmcology, 21, 116 – 118.
(2003). Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. Journal of Neurosciences, 23, 11461 – 11468.
(2009). Attention deficit hyperactivity disorder and critical incidents in a Scottish prison population. Personality and Individual Differences, 46, 265 – 269.
(2004). Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatric Clinics of North America, 27, 283 – 301.
(2008). Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders. Drug and Alcohol Dependence, 96, 145 – 154.
(1997). Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. Journal of Nervous and Mental Disease, 185, 475 – 482.
(2005). Influence of parental SUD and ADHD on ADHD in their offspring: preliminary results from a pilot-controlled family study. American Journal of Addiction, 14, 179 – 187.
(1979). Sensation Seeking: beyond the optimal level of arousal. Hillsdale/NJ: Lawrence Erlbaum.
(